What is the official website of Fresenius Kabi Portugal ?

The official website of Fresenius Kabi Portugal is https://www.fresenius-kabi.com/pt.

What is Fresenius Kabi Portugal's cybersecurity risk score?

Fresenius Kabi Portugal has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Fresenius Kabi Portugal experienced?

According to Rankiteo, Fresenius Kabi Portugal currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Fresenius Kabi Portugal been affected by any supply chain cyber incidents ?

According to Rankiteo, Fresenius Kabi Portugal has been affected by a supply chain cyber incident involving Fresenius Kabi USA, with the incident ID FRE1781735374.

Does Fresenius Kabi Portugal have SOC 2 Type 1 certification ?

According to Rankiteo, Fresenius Kabi Portugal is not certified under SOC 2 Type 1.

Does Fresenius Kabi Portugal have SOC 2 Type 2 certification ?

According to Rankiteo, Fresenius Kabi Portugal does not hold a SOC 2 Type 2 certification.

Does Fresenius Kabi Portugal comply with GDPR ?

According to Rankiteo, Fresenius Kabi Portugal is not listed as GDPR compliant.

Does Fresenius Kabi Portugal have PCI DSS certification ?

According to Rankiteo, Fresenius Kabi Portugal does not currently maintain PCI DSS compliance.

Does Fresenius Kabi Portugal comply with HIPAA ?

According to Rankiteo, Fresenius Kabi Portugal is not compliant with HIPAA regulations.

Does Fresenius Kabi Portugal have ISO 27001 certification ?

According to Rankiteo,Fresenius Kabi Portugal is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Fresenius Kabi Portugal operate in ?

Fresenius Kabi Portugal operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Fresenius Kabi Portugal have ?

Fresenius Kabi Portugal employs approximately 134 people worldwide.

Does Fresenius Kabi Portugal own any subsidiaries ?

Fresenius Kabi Portugal presently has no subsidiaries across any sectors.

How many LinkedIn followers does Fresenius Kabi Portugal have ?

Fresenius Kabi Portugal's official LinkedIn profile has approximately 11,431 followers.

What is the NAICS classification code for Fresenius Kabi Portugal ?

Fresenius Kabi Portugal is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Fresenius Kabi Portugal have a Crunchbase profile ?

No, Fresenius Kabi Portugal does not have a profile on Crunchbase.

Does Fresenius Kabi Portugal have a LinkedIn profile ?

Yes, Fresenius Kabi Portugal maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/fresenius-kabi-portugal.

How many cybersecurity incidents has Fresenius Kabi Portugal experienced ?

As of July 22, 2026, Rankiteo reports that Fresenius Kabi Portugal has experienced 3 cybersecurity incidents.

How many peer or competitor companies does Fresenius Kabi Portugal have ?

Fresenius Kabi Portugal has an estimated 5,710 peer or competitor companies worldwide.

What types of cybersecurity incidents has Fresenius Kabi Portugal faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

FKP

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Fresenius Kabi Portugal Vendor Cyber Rating & Cyber Score

fresenius-kabi.com

Add Your Compliance Badge

Como empresa global de cuidados de saúde, a Fresenius Kabi está Comprometida com a Vida. Os nossos produtos, tecnologias e serviços destinam-se ao tratamento de doentes críticos e crónicos. Com mais de 43.000 colaboradores e presença em mais de 100 países, o nosso vasto portefólio de produtos centra-se em proporcionar acesso a medicamentos e tecnologias de elevada qualidade e que permitem salvar vidas. Na área da Biopharma, disponibilizamos medicamentos biossimilares inovadores para doenças autoimunes e oncologia. Como líder de mercado em Nutrição Clínica, dispomos da maior gama de produtos de nutrição entérica e parentérica. A área de MedTech disponibiliza bombas de infusão, dispositivos de monitorização de anestesia, tecnologias de

FKP A.I CyberSecurity Scoring

Scoring History

FKP

Fresenius Kabi Portugal CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Fresenius Kabi USA

Breach

100

1/2026

Fresenius Kabi ...

FRE1781735374

Fresenius Group

Ransomware

100

5/2020

FRE1770566194

Fresenius Kabi Port...

Ransomware

05/2020

FRE2038291222

Loading…

A.I.

FKP Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for FKP

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Portugal in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Fresenius Kabi Portugal in 2026.

Incident Types FKP vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Portugal in 2026.

Incident History - FKP (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Fresenius Kabi Portugal Subsidiaries

FKP

Pharmaceutical Manufacturing

Website: https://www.fresenius-kabi.com/pt

Company Size: 501-1,000 employees

Fresenius KabiPharmaceutical Manufacturing

Fresenius GroupHospitals and Health Care

Fresenius Investor RelationsHospitals and Health Care

Helios Health GmbHHospitals and Health Care

Fenwal, Inc., a Fresenius Kabi CompanyMedical Equipment Manufacturing

Fresenius Kabi South AfricaPharmaceutical Manufacturing

Fresenius Kabi DanmarkPharmaceutical Manufacturing

Fresenius Kabi IrelandPharmaceutical Manufacturing

Fresenius Kabi NetherlandsPharmaceutical Manufacturing

Fresenius Kabi BelgiumPharmaceutical Manufacturing

Fresenius Kabi USAPharmaceutical Manufacturing

Fresenius Kabi SchweizPharmaceutical Manufacturing

Fresenius Kabi Puerto RicoManufacturing

Fresenius Kabi BrasilPharmaceutical Manufacturing

Fresenius Kabi (Singapore) Pte Ltd, SingaporePharmaceutical Manufacturing

Fresenius Kabi EcuadorPharmaceutical Manufacturing

Fresenius Kabi EspañaPharmaceutical Manufacturing

Fresenius Kabi EuropePharmaceutical Manufacturing

Fresenius Kabi AustriaPharmaceutical Manufacturing

Fresenius Kabi Australia and New ZealandPharmaceutical Manufacturing

Fresenius Kabi Business ServicesAccounting

Fresenius Kabi FrancePharmaceutical Manufacturing

Fresenius Kabi UKPharmaceutical Manufacturing

MOTIV eLearningHospitals and Health Care

Fresenius Kabi PolskaPharmaceutical Manufacturing

Fresenius Kabi ItaliaPharmaceutical Manufacturing

Fresenius Kabi ArgentinaPharmaceutical Manufacturing

Fresenius Kabi ChilePharmaceutical Manufacturing

Fresenius Kabi ColombiaPharmaceutical Manufacturing

Fresenius Kabi MedTech EuropeMedical Equipment Manufacturing

Fresenius Kabi CanadaPharmaceutical Manufacturing

Loading…

Fresenius Kabi Portugal Similar Companies

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Loading…

NEWS

Fresenius Kabi Portugal CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 22, 2021 08:00 AM

FDA, CISA Warn of Fresenius Kabi Infusion Pump Flaws

US government authorities have issued an advisory warning about remotely exploitable security vulnerabilities in certain Fresenius Kabi infusion pump systems.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-63261

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-72/388575

CVE-2026-63260

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-71/388574

CVE-2026-63259

SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-9-4-4-security-update-esa-2026-70/388573

CVE-2026-63145

SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-69/388572

CVE-2026-63144

SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-19-9-3-8-9-4-4-security-update-esa-2026-68/388571

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…